



THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

**S\$225,000,000 4.80% NOTES DUE 2022 TO BE ISSUED PURSUANT TO THE S\$500,000,000
MULTICURRENCY DEBT ISSUANCE PROGRAMME OF THOMSON MEDICAL GROUP LIMITED**

The Board of Directors of Thomson Medical Group Limited (the "**Company**") wishes to announce that it has launched and priced S\$225,000,000 in aggregate principal amount of 4.80% notes due 2022 (the "**Series 001 Notes**"). The Series 001 Notes will be issued by the Company, as issuer, pursuant to the S\$500,000,000 Multicurrency Debt Issuance Programme established by the Company on 28 June 2019 (the "**Programme**"). DBS Bank Ltd., Credit Suisse (Singapore) Ltd. and Maybank Kim Eng Securities Pte. Ltd. have been appointed as the joint lead managers and joint bookrunners in relation to the Series 001 Notes.

The principal terms of the Series 001 Notes are as follows:

Issue Size: **S\$225,000,000**

Issue Price: **100.00% of the principal amount of the Series 001 Notes**

Denomination: **S\$250,000**

Interest: **4.80% per annum payable semi-annually in arrear**

Maturity Date: **3 years from the date of issue**

Interest Reserve: The Series 001 Notes will have the benefit of security over an interest service reserve account in which the Company will maintain an amount equivalent to one interest payment on the Series 001 Notes at all times.

The Series 001 Notes are expected to be issued on 18 July 2019 (subject to satisfaction of customary closing conditions) and listed on the Singapore Exchange Securities Trading Limited ("SGX-ST**") on the market day after such issue.**

The Series 001 Notes will constitute direct, unconditional and unsubordinated obligations of the Company and shall at all times rank *pari passu*, without any preference or priority among themselves, and at least *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Company. The Series 001 Notes will be secured by a charge over an interest service reserve account as mentioned above.

The Series 001 Notes are offered by the Company in Singapore pursuant to the exemptions invoked under Sections 274 and/or 275 of the Securities and Futures Act, Chapter 289 of Singapore.

The net proceeds arising from the issue of the Series 001 Notes under the Programme (after deducting issue expenses) will be used for refinancing of certain existing loan facilities.

Application will be made to the SGX-ST for the listing and quotation of the Series 001 Notes on the SGX-ST. Such permission will be granted when the Series 001 Notes have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 001 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Company, its subsidiaries, its associated companies (if any), the Programme or the Series 001 Notes.

By Order of the Board

Wilson Sam
Executive Director and Chief Financial Officer
11 July 2019